<div id="readability-page-1">Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post EPS of $0.56, implying a fall of nearly 19% while revenue is expected to decline about 9% to $3.46 billion during the quarter. Over the last one year, V...</div>

暉致

<p>製藥公司暉致（NASDAQ:VTRS）將在週四公佈其第二季度財報，華爾街預計每股收益（EPS）為 0.56 美元，下降 19%，收入為 34.6 億美元，下降 9%。暉致在過去一年中 75% 的時間裏超出了每股收益和收入的預期。該股今年已下跌近 29%，主要歸因於產品線的挫折和研發失敗，導致分析師將其評級為持有。最近的修訂顯示每股收益和收入預期的變化喜憂參半</p>

暉致第二季度財報即將發佈：有哪些值得期待的內容